Quick Answer
Karyopharm Therapeutics Inc. reported Net Income Loss of -$196.04 million for the year ending 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -156.5% in Net Income Loss from 2024 to 2025.
- This data is from Karyopharm Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$13.69 million | Q2 2014: -$16.43 million | Q3 2014: -$19.72 million | Q4 2014: -$25.93 million | Q1 2015: -$26.07 million | Q2 2015: -$32.70 million | Q3 2015: -$30.37 million | Q4 2015: -$29.05 million | Q1 2016: -$27.06 million | Q2 2016: -$30.16 million | Q3 2016: -$25.43 million | Q4 2016: -$26.94 million | Q1 2017: -$29.92 million | Q2 2017: -$29.39 million | Q3 2017: -$30.64 million | Q4 2017: -$39.04 million | Q1 2018: -$38.46 million | Q2 2018: -$33.66 million | Q3 2018: -$48.08 million | Q4 2018: -$58.21 million | Q1 2019: -$66.16 million | Q2 2019: -$43.42 million | Q3 2019: -$41.37 million | Q1 2020: -$52.93 million | Q2 2020: -$46.43 million | Q3 2020: -$53.50 million | Q1 2021: -$57.41 million | Q2 2021: -$53.58 million | Q3 2021: -$51.81 million | Q1 2022: -$41.40 million | Q2 2022: -$49.06 million | Q3 2022: -$36.32 million | Q1 2023: -$34.13 million | Q2 2023: -$32.63 million | Q3 2023: -$34.51 million | Q1 2024: -$37.36 million | Q2 2024: $23.79 million | Q3 2024: -$32.07 million | Q1 2025: -$23.46 million | Q2 2025: -$37.25 million | Q3 2025: -$33.13 million.
- Over the full 14 years of available data (2012 to 2025), Karyopharm Therapeutics Inc.'s Net Income Loss has declined by 1,133.9%.
- Historical annual values: Fiscal year 2025: -$196.04 million | Fiscal year 2024: -$76.42 million | Fiscal year 2023: -$143.10 million | Fiscal year 2022: -$165.29 million | Fiscal year 2021: -$124.09 million | Fiscal year 2020: -$196.27 million | Fiscal year 2019: -$199.59 million | Fiscal year 2018: -$178.41 million | Fiscal year 2017: -$128.98 million | Fiscal year 2016: -$109.58 million | Fiscal year 2015: -$118.18 million | Fiscal year 2014: -$75.78 million | Fiscal year 2013: -$33.95 million | Fiscal year 2012: -$15.89 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: